Immunitybio, Inc.

This early-stage study is testing a new treatment for people with advanced solid tumors that have spread. The treatment uses a patient's own immune cells, called M-CENK, which are collected, processed, and given back along with a booster drug called N-803. The main goal is to see…

This study tests whether adding an immune-boosting drug called N-803 to the standard BCG treatment works better than BCG alone for people with a high-risk type of bladder cancer that hasn't invaded the muscle. About 369 participants will receive either the combination or BCG alon…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This study aimed to see if adding ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade type of bladder cancer that hasn't spread into the muscle. It was designed for adults with papillary tumors who had not received BCG before or had limited …

This study was designed to test whether adding an experimental drug and special immune cells to standard care could help critically ill adults with severe pneumonia, especially those with sepsis or lung failure. The trial was withdrawn before enrolling any participants, so no res…

This study tests whether adding a combination of immunotherapy drugs (aldoxorubicin, N-803, and PD-L1 t-haNK) to standard chemotherapy can help people with advanced pancreatic cancer live longer without their disease getting worse. About 328 adults with locally advanced or metast…

This early-stage trial tests a new drug called IBRX-042 in 12 people with HPV-related cancers that have come back or worsened. The main goal is to find the safest dose and understand side effects. Participants get three injections, one every three weeks, and are closely monitored…

This study tests a new treatment for people with a type of bladder cancer that has not improved with standard therapy. The treatment combines a standard immunotherapy (BCG) with an experimental drug (N-803), both given directly into the bladder through a catheter. The goal is to …

This study was designed to see if adding two immune treatments (NAI and iNKT cells) to standard care could help critically ill adults with severe pneumonia, sepsis, or lung failure recover. It planned to enroll ICU patients and follow them for 90 days. However, the study was with…

This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from…

This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to combine three experimental drugs (N-803, ETBX-071, and M-CENK) with radiation to boost the immune system's attack on cancer. Researchers aimed to see if the treatment could elimi…

This study follows 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. Researchers will collect long-term data on survival, cancer recurrence, and test results to see how well the treatment worked over time. No new…